Similar to human vaccines, animal vaccines are administered to prevent diseases from occurring in animals. Routinely vaccinating animals is often more affordable than paying for the treatment of sick animals, reduces transmission of microorganisms in the animal population, and reduces animal suffering. Pets are often given vaccines for infectious diseases such as rabies, parvovirus, distemper and hepatitis. Livestock animals, such as turkeys, chickens and cattle, are vaccinated to protect against diseases such as rotavirus, E. coli, pinkeye and brucellosis.
The proper application of vaccines to animal populations has enhanced their health and welfare, and prolonged their life expectancies. The goal of a vaccination program is to prevent or reduce disease, and thereby promote optimal patient, herd and public health. Even though some formerly common diseases have now become uncommon, vaccination is still highly recommended because these serious disease agents continue to thrive in certain environments.
Types of Animal Vaccines
Animal vaccines are part of a broader category of animal medicines called veterinary biologics (VB). VB products work primarily through the stimulation of the immune system in order to prevent or treat diseases.
At Dyadic we are focused on transforming the veterinary biologics (VB) market for both companion and livestock animals by using our C1 technology to help develop and commercialize novel biologic therapies that provide greater immunogenicity and challenge the conventional cost of goods and CAPEX considerations to provide better healthcare and reduce costs of treating companion animals and livestock animals.
The opportunity in animal health for C1
There has been very limited activity in therapeutic veterinary biologics compared to human medicine with only a small number of marketing approvals issued in the U.S. or EU.
We believe this creates a significant opportunity for us to help animal health companies develop first-in-class therapeutics for the unmet medical needs of companion and livestock animals.
We believe a number of factors have prevented mAbs from reaching the animal health market, which potentially C1 can help address:
o Research and development priorities. We believe that constrained research and development budgets have contributed to major pharmaceutical companies, their animal health divisions and our competitors focusing on small molecule therapies, reformulations and line extensions while overlooking mAbs as a development priority.
o Development and manufacturing costs. There is a perceived high cost associated with the development and manufacture of mAbs and therapeutic proteins at commercial scale. Our C1 platform is designed to develop mAb therapeutics cost-effectively.
o Immunogenicity. Improperly designed biologics can induce a significant negative immune response or immunogenicity. This is the body’s reaction to the identification of foreign material, resulting in the biologic being inactivated and cleared from the body, thereby diminishing or removing its therapeutic effect.